Language: BG BG
← Back to results
Active (not recruiting) Phase 1 2023-505479-56-00

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Phase 1 – testing safety in a small group of people
Conditions: Follicular lymphoma (FL) Chronic lymphocytic leukemia (CLL) Diffuse large b-cell lymphoma (DLBCL) B-cell malignancies

Sponsor: AbbVie Deutschland GmbH & Co. KG

trial.available_in: БГ
Overview
Trial status: Authorised
Who can participate
Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 44 participants
Locations 3
France (1)
Italy (1)
Spain (1)
Technical details
Status
Active (not recruiting)
Phase
Phase 1
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
14.07.2025
Registry ID
2023-505479-56-00
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.